Catalyst Event
DICK'S Sporting Goods Inc (DKS) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
5/28/2026, 12:00:00 AM
CEO Lauren Hobart sold 20,083 shares for approximately $4.58 million following an option exercise. This was part of broader insider selling totaling $42.5 million over the prior three months with no insider purchases reported.
Korean Translation
CEO 로렌 호바트(Lauren Hobart)가 옵션 행사 후 약 458만 달러 상당의 주식 20,083주를 매도함. 이는 지난 3개월 동안 내부자 매수 없이 총 4,250만 달러에 달하는 내부자 매도 흐름의 일부임.
Related Recent Events
Abbott Laboratories (ABT) · Earnings Release
Abbott's Q2 2026 earnings release is scheduled for July 16, 2026. Analysts forecast EPS of $1.28. Medium importance estimated as earnings typically drive >5% price movement expected.
7/16/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Other
Quarterly cash dividend of $1.25 per share has an ex-dividend date of June 12, 2026. The dividend is scheduled to be paid on June 26, 2026.
6/12/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Other
New Phase 3 data for the pipeline drug CagriSema to be presented at the American Diabetes Association (ADA) Scientific Sessions on June 7, 2026, with a low price impact scheduled.
6/7/2026, 12:00:00 AM
Lululemon Athletica Inc (LULU) · Earnings Release
Lululemon Athletica is scheduled to release its financial results for the first quarter of fiscal 2026 on June 4, 2026, after the market closes. High importance is estimated as earnings releases typically result in significant price volatility. scheduled
6/4/2026, 12:00:00 AM
Life Time Group Holdings Inc (LTH) · Other
RBC Capital analysts forecast a price target of $43.00 for Life Time Group Holdings on June 2, 2026; target increases typically suggest a low positive impact, forecasted.
6/2/2026, 12:00:00 AM
Astrazeneca PLC (AZN) · Other
Positive results from the EMERALD-3 Phase III trial were presented at the ASCO 2026 meeting on 2026-06-01, showing that Imfinzi and Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in patients with unresectable liver cancer; high market impact (>=10%) expected due to significant clinical efficacy.
6/1/2026, 12:00:00 AM